Protocol Ledger

NCT03654053 · Phase III · ACTIVE NOT RECRUITING

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

Interventional Phase III clinical trial protocol NCT03654053 sponsored by VA Office of Research and Development in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-02 Enrollment: 142 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03654053
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)142 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03654053
Protocol FieldVerified Registry Value
NCT IdentifierNCT03654053
Consolidated Lead SponsorVA Office of Research and Development
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment142 participants (ACTUAL)
Registered Start Date2020-10-02
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI